Rifamycin Sodium

利福霉素钠

Report date: 2022/03/15 14:36:52
QIDP

Base Information

Drug NameRifamycin Sodium
Drug Alias NameRifamycin-SV-sodium利福霉素SVRifamycin SV力复霉素Rifamycin CR +[14] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionDNA-directed RNA polymerase beta chain inhibitorsBacterial DNA-directed RNA polymerase inhibitors
TargetsDNA-directed RNA polymerase beta chainBacterial DNA-directed RNA polymerase
Therapy Area/IndicationsDiarrheaIrritable Bowel SyndromeDiverticulitis +[5] 
Global Approved IndicationsTuberculosis, PulmonaryGram-Positive Bacterial Infections
Approved Indications in ChinaGram-Positive Bacterial Infections
Original Approved Country/TerritoryMainland China
Original Approved Date1981/01/01
Country/TerritoryBelgiumUnited StatesMexico +[11] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesRedhill Biopharma LtdSandoz GmbhAdalvo Ltd +[4] 
Inactive CompaniesDr Falk Pharma GmbHCosmo Technologies LtdBausch Health Americas Inc
Active IndicationsDiarrheaTuberculosis, PulmonaryGram-Positive Bacterial Infections
Inactive IndicationsIrritable Bowel SyndromeDiverticulitis

Other Information

ATC CodeA07AA13D06AX15J04AB03 +[5] 
Related LinksWikipediaDrugBankKEGG